Franz Hofmann

Dr. Franz Hofmann


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2011 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SFStefan Frantz
Stefan Frantz
MKMichael Klaiber
Michael Klaiber
HBHideo Baba
Hideo Baba
HOHeike Oberwinkler
Heike Oberwinkler
KVKatharina Völker
Katharina Völker
MKMichaela Kuhn
Michaela Kuhn
Cardiac hypertrophy is a common and often lethal complication of arterial hypertension. Elevation of myocyte cyclic GMP levels by local actions of endogenous atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) or by pharmacological inhibition of phosphodiesterase-5 was shown to counter-regulate pathological hypertrophy. It was suggested that cGMP-dependent protein kinase I (cGKI) mediates this protective effect, although the role in vivo is under debate. Here, we investigated whether cGKI modulates myocyte growth and/or function in the intact organism. To circumvent the systemic phenotype associated with germline ablation of cGKI, we inactivated the murine cGKI gene selectively in cardiomyocytes by Cre/loxP-mediated recombination. Mice with cardiomyocyte-restricted cGKI deletion exhibited unaltered cardiac morphology and function under resting conditions. Also, cardiac hypertrophic and contractile responses to β-adrenoreceptor stimulation by isoprenaline (at 40 mg/kg/day during 1 week) were unaltered. However, angiotensin II (Ang II, at 1000 ng/kg/min for 2 weeks) or transverse aortic constriction (for 3 weeks) provoked dilated cardiomyopathy with marked deterioration of cardiac function. This was accompanied by diminished expression of the [Ca2+]i-regulating proteins SERCA2a and phospholamban (PLB) and a reduction in PLB phosphorylation at Ser16, the specific target site for cGKI, resulting in altered myocyte Ca2+i homeostasis. In isolated adult myocytes, CNP, but not ANP, stimulated PLB phosphorylation, Ca2+i-handling, and contractility via cGKI. These results indicate that the loss of cGKI in cardiac myocytes compromises the hypertrophic program to pathological stimulation, rendering the heart more susceptible to dysfunction. In particular, cGKI mediates stimulatory effects of CNP on myocyte Ca2+i handling and contractility.

1 November 2019 in Biological Chemistry
Verified
Journal Article
Open access
PDF file
FHFranz Hofmann
Franz Hofmann
The cyclic guanosine monophosphate (cGMP) signaling system is one of the most prominent regulators of a variety of physiological and pathophysiological processes in many mammalian and non-mammalian tissues. Targeting this pathway by increasing cGMP levels has been a very successful approach in pharmacology as shown for nitrates, phosphodiesterase (PDE) inhibitors and stimulators of nitric oxide-guanylyl cyclase (NO-GC) and particulate GC (pGC). This is an introductory review to the cGMP signaling system intended to introduce those readers to this system, who do not work in this area. This article does not intend an in-depth review of this system. Signal transduction by cGMP is controlled by the generating enzymes GCs, the degrading enzymes PDEs and the cGMP-regulated enzymes cyclic nucleotide-gated ion channels, cGMP-dependent protein kinases and cGMP-regulated PDEs. Part A gives a very concise introduction to the components. Part B gives a very concise introduction to the functions modulated by cGMP. The article cites many recent reviews for those who want a deeper insight.

19 August 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EPEnrico Patrucco
Enrico Patrucco
KDKatrin Domes
Katrin Domes
MSMauro Sbroggió
Mauro Sbroggió
ABAnne Blaich
Anne Blaich
JSJens Schlossmann
Jens Schlossmann
FHFranz Hofmann
Franz Hofmann
Conflicting results have been reported for the roles of cGMP and cGMP-dependent protein kinase I (cGKI) in various pathological conditions leading to cardiac hypertrophy and fibrosis. A cardioprotective effect of cGMP/cGKI has been reported in whole animals and isolated cardiomyocytes, but recent evidence from a mouse model expressing cGKIβ only in smooth muscle (βRM) but not in cardiomyocytes, endothelial cells, or fibroblasts has forced a reevaluation of the requirement for cGKI activity in the cardiomyocyte antihypertrophic effects of cGMP. In particular, βRM mice developed the same hypertrophy as WT controls when subjected to thoracic aortic constriction or isoproterenol infusion. Here, we challenged βRM and WT (Ctr) littermate control mice with angiotensin II (AII) infusion (7 d; 2 mg⋅kg−1⋅d−1) to induce hypertrophy. Both genotypes developed cardiac hypertrophy, which was more pronounced in Ctr animals. Cardiomyocyte size and interstitial fibrosis were increased equally in both genotypes. Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effect in reducing myocyte hypertrophy in WT mice and no effect in βRM mice. However, sildenafil substantially blocked the increase in collagen I, fibronectin 1, TGFβ, and CTGF mRNA in Ctr but not in βRM hearts. These data indicate that, for the initial phase of AII-induced cardiac hypertrophy, lack of cardiomyocyte cGKI activity does not worsen hypertrophic growth. However, expression of cGKI in one or more cell types other than smooth muscle is necessary to allow the antifibrotic effect of sildenafil.

1 August 2014 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
RLRobert Lukowski
Robert Lukowski
TKThomas Krieg
Thomas Krieg
SRSergei D. Rybalkin
Sergei D. Rybalkin
JBJoseph Beavo
Joseph Beavo
FHFranz Hofmann
Franz Hofmann

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAnne Blaich
Anne Blaich
SPSara Pahlavan
Sara Pahlavan
QTQinghai Tian
Qinghai Tian
MOMartin Oberhofer
Martin Oberhofer
MPMontatip Poomvanicha
Montatip Poomvanicha
FHFranz Hofmann
Franz Hofmann
Cardiac excitation-contraction coupling (EC coupling) links the electrical excitation of the cell membrane to the mechanical contractile machinery of the heart. Calcium channels are major players of EC coupling and are regulated by voltage and Ca2+/calmodulin (CaM). CaM binds to the IQ motif located in the C terminus of the Cav1.2 channel and induces Ca2+-dependent inactivation (CDI) and facilitation (CDF). Mutation of Ile to Glu (Ile1624Glu) in the IQ motif abolished regulation of the channel by CDI and CDF. Here, we addressed the physiological consequences of such a mutation in the heart. Murine hearts expressing the Cav1.2I1624E mutation were generated in adult heterozygous mice through inactivation of the floxed WT Cav1.2L2 allele by tamoxifen-induced cardiac-specific activation of the MerCreMer Cre recombinase. Within 10 days after the first tamoxifen injection these mice developed dilated cardiomyopathy (DCM) accompanied by apoptosis of cardiac myocytes (CM) and fibrosis. In Cav1.2I1624E hearts, the activity of phospho-CaM kinase II and phospho-MAPK was increased. CMs expressed reduced levels of Cav1.2I1624E channel protein and ICa. The Cav1.2I1624E channel showed “CDI” kinetics. Despite a lower sarcoplasmic reticulum Ca2+ content, cellular contractility and global Ca2+ transients remained unchanged because the EC coupling gain was up-regulated by an increased neuroendocrine activity. Treatment of mice with metoprolol and captopril reduced DCM in Cav1.2I1624E hearts at day 10. We conclude that mutation of the IQ motif to IE leads to dilated cardiomyopathy and death.

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JBJulia Brandmayr
Julia Brandmayr
MPMontatip Poomvanicha
Montatip Poomvanicha
KDKatrin Domes
Katrin Domes
JDJie Ding
Jie Ding
ABAnne Blaich
Anne Blaich
FHFranz Hofmann
Franz Hofmann
Phosphorylation of the cardiac β subunit (Cavβ2) of the Cav1.2 L-type Ca2+ channel complex has been proposed as a mechanism for regulation of L-type Ca2+ channels by various protein kinases including PKA, CaMKII, Akt/PKB, and PKG. To test this hypothesis directly in vivo, we generated a knock-in mouse line with targeted mutation of the Cavβ2 gene by insertion of a stop codon after proline 501 in exon 14 (mouse sequence Cacnb2; βStop mouse). This mutation prevented translation of the Cavβ2 C terminus that contains the relevant phosphorylation sites for the above protein kinases. Homozygous cardiac βStop mice were born at Mendelian ratio, had a normal life expectancy, and normal basal L-type ICa. The regulation of the L-type current by stimulation of the β-adrenergic receptor was unaffected in vivo and in cardiomyocytes (CMs). βStop mice were cross-bred with mice expressing the Cav1.2 gene containing the mutation S1928A (SAβStop) or S1512A and S1570A (SFβStop) in the C terminus of the α1C subunit. The β-adrenergic regulation of the cardiac ICa was unaltered in these mouse lines. In contrast, truncation of the Cav1.2 at Asp1904 abolished β-adrenergic up-regulation of ICa in murine embryonic CMs. We conclude that phosphorylation of the C-terminal sites in Cavβ2, Ser1928, Ser1512, and Ser1570 of the Cav1.2 protein is functionally not involved in the adrenergic regulation of the murine cardiac Cav1.2 channel.